Overweight

Microtia

Endotoxemia

Metabolic Syndrome

Insulin Resistance

Non-Alcoholic Fatty Liver Disease

3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks

Camu camu

3 capsules of placebo daily during 12 weeks

Placebo

Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans

Evaluation of fat accumulation by magnetic resonance imaging (MRI)

Plasma Lipopolysaccharides (LPS) and Lipopolysaccharide Binding Protein (LBP)

Measure short chain fatty acids in the feces

Evaluation of gastrointestinal symptoms using a standardized questionnaire (the gastrointestinal symptom rating scale (GSRS))

Evaluation of stool consistency using a standardized questionnaire (Bristol stool chart)

Evaluation of plasma glucose using a 3-hour oral glucose tolerance test

Evaluation of insulin concentration using a 3-hour oral glucose tolerance test

Evaluation of c-peptide concentration using a 3-hour oral glucose tolerance test

Evaluation of plasma triglycerides (TG), Total cholesterol, LDL, HDL, Apolipoprotein B and free fatty acids

Evaluation of BMI (measured with weight change and height throughout the protocol)

Evaluation of body composition by osteodensitometry

Evaluation of plasma high sensitive C-Reactive Protein (hs-CRP)

Evaluation of aspartate transaminase and alanine aminotransferase (AST and ALT)

Transcriptomic analyses to investigate underlying mechanisms of action

Evaluation of camu-camu derived metabolites, short chain fatty acids, branched chain fatty acids, bile acids, phenolic compounds

Evaluation of metabolome: camu-camu derived metabolites, short chain fatty acids, branched chain fatty acids, bile acids, phenolic compounds

Evaluation of systolic and diastolic blood pressure

André Marette

Professor

Laval University

Patients affected by acute or acute on chronic liver failure who undergo Coupled plasma filtration and adsorption (CPFA) to recover their basal liver function or as a bridge to liver transplantation. The intervention is CPFA treatment which lasts 6 hour length. The intervention can be repeated for a maximum of 5 times.

Liver Failure, Acute

Liver Failure, Acute on Chronic

Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a "bridge" to liver transplantation

Coupled plasma filtration and adsorption (CPFA)

Nephrology Dialysis and Renal Transplantation Unit, S.Orsola University Hospital

HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification

The measure is the overall survival of the patients after CPFA and standard medical therapy

The measures of efficacy consist in the evaluation bilirubin levels, biliary acids levels, ammonia levels and lactate levels

The measure of hepatic encephalopathy is assessed by means of the West Haven Criteria

Measuring arterial blood pressure (mmHg) on starting CPFA, during the CPFA treatment and at CPFA end.

Blood leukocytes, platelets, Hemoglobin are assessed before and after each CPFA treatment

Interleukin-6, Tumor Necrosis Factor alfa, Interleukin-10, Hepatocyte growth factor are assessed before and after each CPFA treatment

cholic acid/التهاب

Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans

HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم